Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...

For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Blood centres cannot make cell therapies more accessible on their own. For decades they have partnered with hospitals to ...